These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31134296)

  • 1. MR imaging phenotype correlates with extent of genome-wide copy number abundance in IDH mutant gliomas.
    Wu CC; Jain R; Neto L; Patel S; Poisson LM; Serrano J; Ng V; Patel SH; Placantonakis DG; Zagzag D; Golfinos J; Chi AS; Snuderl M
    Neuroradiology; 2019 Sep; 61(9):1023-1031. PubMed ID: 31134296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Signatures of Chromosomal Instability Correlate With Copy Number Variation Patterns and Patient Outcome in IDH-Mutant and IDH-Wildtype Astrocytomas.
    Richardson TE; Sathe AA; Xing C; Mirchia K; Viapiano MS; Snuderl M; Abdullah KG; Hatanpaa KJ; Walker JM
    J Neuropathol Exp Neurol; 2021 Mar; 80(4):354-365. PubMed ID: 33755138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive Assessment of
    Xing Z; Yang X; She D; Lin Y; Zhang Y; Cao D
    AJNR Am J Neuroradiol; 2017 Jun; 38(6):1138-1144. PubMed ID: 28450436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The reliability and interobserver reproducibility of T2/FLAIR mismatch in the diagnosis of IDH-mutant astrocytomas.
    Yeniçeri İÖ; Yıldız ME; Özduman K; Danyeli AE; Pamir MN; Dinçer A
    Diagn Interv Radiol; 2021 Nov; 27(6):796-801. PubMed ID: 34792037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
    Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
    Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
    Richardson TE; Snuderl M; Serrano J; Karajannis MA; Heguy A; Oliver D; Raisanen JM; Maher EA; Pan E; Barnett S; Cai C; Habib AA; Bachoo RM; Hatanpaa KJ
    J Neurooncol; 2017 May; 133(1):183-192. PubMed ID: 28421459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomas.
    Mirchia K; Snuderl M; Galbraith K; Hatanpaa KJ; Walker JM; Richardson TE
    Acta Neuropathol Commun; 2019 Jul; 7(1):121. PubMed ID: 31349875
    [No Abstract]   [Full Text] [Related]  

  • 8. T2-FLAIR Mismatch: An Imaging Biomarker for Children's
    van Maren EA; Dankbaar JW; Wesseling P; Plasschaert S; Muhlebner A; Hoving EW; Robe PA; Snijders TJ; Hoogendijk R; Kranendonk MEG; Lequin MH
    AJNR Am J Neuroradiol; 2024 Jun; 45(6):747-752. PubMed ID: 38724203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total copy number variation as a prognostic factor in adult astrocytoma subtypes.
    Mirchia K; Sathe AA; Walker JM; Fudym Y; Galbraith K; Viapiano MS; Corona RJ; Snuderl M; Xing C; Hatanpaa KJ; Richardson TE
    Acta Neuropathol Commun; 2019 Jun; 7(1):92. PubMed ID: 31177992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI features predict tumor grade in isocitrate dehydrogenase (IDH)-mutant astrocytoma and oligodendroglioma.
    Joyner DA; Garrett J; Batchala PP; Rama B; Ravicz JR; Patrie JT; Lopes MB; Fadul CE; Schiff D; Jain R; Patel SH
    Neuroradiology; 2023 Jan; 65(1):121-129. PubMed ID: 35953567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of T2-FLAIR Mismatch in Nonenhancing Diffuse Gliomas Using Digital Subtraction.
    Cho NS; Sanvito F; Le VL; Oshima S; Teraishi A; Yao J; Telesca D; Raymond C; Pope WB; Nghiemphu PL; Lai A; Cloughesy TF; Salamon N; Ellingson BM
    AJNR Am J Neuroradiol; 2024 Feb; 45(2):188-197. PubMed ID: 38238098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlating MRI features with additional genetic markers and patient survival in histological grade 2-3 IDH-mutant astrocytomas.
    Lasocki A; Buckland ME; Molinaro T; Xie J; Whittle JR; Wei H; Gaillard F
    Neuroradiology; 2023 Aug; 65(8):1215-1223. PubMed ID: 37316586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling MR and clinical features in grade II/III astrocytomas to predict IDH mutation status.
    Hyare H; Rice L; Thust S; Nachev P; Jha A; Milic M; Brandner S; Rees J
    Eur J Radiol; 2019 May; 114():120-127. PubMed ID: 31005161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas.
    Wu CC; Jain R; Radmanesh A; Poisson LM; Guo WY; Zagzag D; Snuderl M; Placantonakis DG; Golfinos J; Chi AS
    AJNR Am J Neuroradiol; 2018 Oct; 39(10):1814-1820. PubMed ID: 30190259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T2-FLAIR mismatch in isocitrate dehydrogenase mutant astrocytomas: Variability and evolution.
    Throckmorton P; Graber JJ
    Neurology; 2020 Sep; 95(11):e1582-e1589. PubMed ID: 32690782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
    Corell A; Ferreyra Vega S; Hoefling N; Carstam L; Smits A; Olsson Bontell T; Björkman-Burtscher IM; Carén H; Jakola AS
    BMC Cancer; 2020 May; 20(1):450. PubMed ID: 32434559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in
    Batchala PP; Muttikkal TJE; Donahue JH; Patrie JT; Schiff D; Fadul CE; Mrachek EK; Lopes MB; Jain R; Patel SH
    AJNR Am J Neuroradiol; 2019 Mar; 40(3):426-432. PubMed ID: 30705071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations.
    Yang RR; Shi ZF; Zhang ZY; Chan AK; Aibaidula A; Wang WW; Kwan JSH; Poon WS; Chen H; Li WC; Chung NY; Punchhi G; Chu WC; Chan IS; Liu XZ; Mao Y; Li KK; Ng HK
    Brain Pathol; 2020 May; 30(3):541-553. PubMed ID: 31733156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Real world" use of a highly reliable imaging sign: "T2-FLAIR mismatch" for identification of IDH mutant astrocytomas.
    Jain R; Johnson DR; Patel SH; Castillo M; Smits M; van den Bent MJ; Chi AS; Cahill DP
    Neuro Oncol; 2020 Jul; 22(7):936-943. PubMed ID: 32064507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing the value of DKI and DTI in detecting isocitrate dehydrogenase genotype of astrocytomas.
    Tan Y; Zhang H; Wang X; Qin J; Wang L; Yang G; Yan H
    Clin Radiol; 2019 Apr; 74(4):314-320. PubMed ID: 30771996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.